India, Feb. 4 -- The shares of the Pharmaceuticals company specializing in the development, manufacturing, and commercialization of complex, high-value generic pharmaceutical formulations are in focus following their Q3 results, with a 91 percent rise in profit and strong R&D spend.

With a market capitalization of Rs. 12,203.88 Crores on Wednesday, the shares of Rubicon Research Ltd jumped up to 9 percent, reaching a high of Rs. 788.85 compared to its previous close of Rs. 723.25.

What Happened Rubicon Research Ltd, engaged in the development, manufacturing, and commercialization of complex, high-value generic pharmaceutical formulations are in the spotlight today as it has announced its Q3 results as follows:

Its Revenue from operatio...